{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:29Z","timestamp":1792460309165,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eclinm.2023.102157","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T18:23:47Z","timestamp":1692901427000},"page":"102157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exposure to medication for neurological disease in pregnancy \u2013 time to consider the long-term implications?"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9019-3421","authenticated-orcid":false,"given":"Chen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bromley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1474-4422(19)30029-8","article-title":"The global burden of neurological disorders","volume":"18","author":"Carroll","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.70.1.15","article-title":"Additional educational needs in children born to mothers with epilepsy","volume":"70","author":"Adab","year":"2001","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eclinm.2023.102157_bib3","series-title":"Births by parents' characteristics","year":"2023"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12884-019-2400-x","article-title":"Maternal age and the risk of adverse pregnancy outcomes: a retrospective cohort study","volume":"19","author":"Londero","year":"2019","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.eclinm.2023.102157_bib5","series-title":"Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers","year":"2018"},{"key":"10.1016\/j.eclinm.2023.102157_bib6","author":"Neligan"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102157_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/JPN.0b013e31829d1d29","article-title":"Epilepsy in pregnancy: best evidence for care","volume":"27","author":"Ruth","year":"2013","journal-title":"J\u00a0Perinat Neonatal Nurs"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1471-0528.2011.03004.x","article-title":"Obstetric outcome in women with epilepsy: a hospital-based, retrospective study","volume":"118","author":"Borthen","year":"2011","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib10","first-page":"CD010224","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"11","author":"Weston","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13023-019-1064-y","article-title":"Diagnosis and management of individuals with fetal valproate spectrum disorder; a consensus statement from the European reference network for congenital malformations and intellectual disability","volume":"14","author":"Clayton-Smith","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.eclinm.2023.102157_bib13","series-title":"Handbook of behavioral teratology","first-page":"23","article-title":"Principles of behavioral teratology","author":"Vorhees","year":"1986"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.yebeh.2011.03.020","article-title":"Relationship of child IQ to parental IQ and education in children with fetal antiepileptic drug exposure","volume":"21","author":"Meador","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102157_bib15","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s11064-017-2262-4","article-title":"Neurodevelopmental effects of antiepileptic drugs","volume":"42","author":"Kellogg","year":"2017","journal-title":"Neurochem Res"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102157_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25570","article-title":"Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones","volume":"3","author":"Daugaard","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102157_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102157_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102157_bib19","first-page":"CD010236","article-title":"Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child","volume":"2020","author":"Bromley","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.0000000000001182","article-title":"IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study","volume":"84","author":"Baker","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74409-x","article-title":"Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France","volume":"10","author":"Coste","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1212\/WNL.62.1.28","article-title":"Normal intelligence in children with prenatal exposure to carbamazepine","volume":"62","author":"Gaily","year":"2004","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102157_bib23","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/1570159X19666210716111814","article-title":"Neurodevelopment following exposure to antiseizure medications in utero: a review","volume":"19","author":"Bromley","year":"2021","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/epi.12226","article-title":"Exposure to antiepileptic drugs in utero and child development: a prospective population-based study","volume":"54","author":"Veiby","year":"2013","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102157_bib25","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1212\/WNL.0000000000006073","article-title":"Verbal abilities in children of mothers with epilepsy","volume":"91","author":"Husebye","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaneurol.2021.5487","article-title":"Antiseizure medication concentrations during pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study","volume":"79","author":"Pennell","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.eclinm.2023.102157_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221088419","article-title":"Neurodevelopmental outcomes in children exposed prenatally to levetiracetam","volume":"13","author":"Alsfouk","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.eclinm.2023.102157_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.seizure.2023.01.008","article-title":"Adaptive behaviour in children exposed to topiramate in the womb: an observational cohort study","volume":"105","author":"Knight","year":"2023","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib29","doi-asserted-by":"crossref","first-page":"405.e1","DOI":"10.1016\/j.ajog.2012.07.008","article-title":"Use of topiramate in pregnancy and risk of oral clefts","volume":"207","author":"Margulis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102157_bib30","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1526-4610.2012.02190.x","article-title":"Utilization of topiramate during pregnancy and risk of birth defects","volume":"52","author":"Green","year":"2012","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102157_bib31","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/pds.3612","article-title":"Topiramate use in pregnancy and the birth prevalence of oral clefts","volume":"23","author":"Mines","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","article-title":"Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register","volume":"71","author":"Hunt","year":"2008","journal-title":"Neurology"},{"issue":"10017","key":"10.1016\/j.eclinm.2023.102157_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(15)01024-7","article-title":"Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect","volume":"387","author":"Victora","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaneurol.2019.4443","article-title":"Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy","volume":"77","author":"Birnbaum","year":"2020","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamapediatrics.2014.118","article-title":"Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years","volume":"168","author":"Meador","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1684\/epd.2022.1492","article-title":"Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force","volume":"24","year":"2022","journal-title":"Epileptic Disord"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/head.12500","article-title":"Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis","volume":"55","author":"Marchenko","year":"2015","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102157_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011971","article-title":"Longitudinal changes in neurodevelopmental outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study","volume":"6","author":"Wood","year":"2016","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ppe.12253","article-title":"Prenatal triptan exposure and internalising and externalising behaviour problems in 3-year-old children: results from the Norwegian Mother and Child Cohort study","volume":"30","author":"Wood","year":"2016","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102157_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ppe.12461","article-title":"Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: follow-up from the Norwegian mother and child cohort study","volume":"32","author":"Harris","year":"2018","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15333","article-title":"Association of maternal use of triptans during pregnancy with risk of attention-deficit\/hyperactivity disorder in offspring","volume":"5","author":"Harris","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib44","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11590370-000000000-00000","article-title":"Delivery outcome after maternal use of drugs for migraine: a register study in Sweden","volume":"34","author":"K\u00e4ll\u00e9n","year":"2011","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102157_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/GRF.0b013e3181b52e20","article-title":"Antidepressant use during pregnancy: current controversies and treatment strategies","volume":"52","author":"Payne","year":"2009","journal-title":"Clin Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJM199701233360404","article-title":"Neurodevelopment of children exposed in utero to antidepressant drugs","volume":"336","author":"Nulman","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00023210-200519060-00001","article-title":"Migraine during pregnancy: options for therapy","volume":"19","author":"Fox","year":"2005","journal-title":"CNS Drugs"},{"issue":"2 Suppl 2","key":"10.1016\/j.eclinm.2023.102157_bib49","first-page":"1","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","year":"2012","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF00607078","article-title":"Metabolism of propranolol in the human maternal-placental-foetal unit","volume":"24","author":"Smith","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ncl.2018.09.004","article-title":"Headache in pregnancy and the puerperium","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol Clin"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib52","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1681\/ASN.2005121303","article-title":"Renal tubular dysgenesis, a not uncommon autosomal recessive disorder leading to oligohydramnios: role of the Renin-Angiotensin system","volume":"17","author":"Lacoste","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10194-009-0182-7","article-title":"Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome","volume":"11","author":"Haaland","year":"2010","journal-title":"J\u00a0Headache Pain"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s10194-020-01196-1","article-title":"OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients","volume":"21","author":"Wong","year":"2020","journal-title":"J\u00a0Headache Pain"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib55","doi-asserted-by":"crossref","first-page":"H230","DOI":"10.1152\/ajpheart.00140.2003","article-title":"Involvement of calcitonin gene-related peptide in control of human fetoplacental vascular tone","volume":"286","author":"Dong","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib56","doi-asserted-by":"crossref","first-page":"H284","DOI":"10.1152\/ajpheart.1999.276.1.H284","article-title":"Pregnancy and steroid hormones enhance the vasodilation responses to CGRP in rats","volume":"276","author":"Gangula","year":"1999","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1043-2760(02)00563-5","article-title":"Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity","volume":"13","author":"Yallampalli","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2023.102157_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4939-1031-1_20","article-title":"Calcitonin gene related family peptides: importance in normal placental and fetal development","volume":"814","author":"Yallampalli","year":"2014","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib59","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1095\/biolreprod.106.059089","article-title":"Calcitonin gene-related peptide (CALCA) is a proangiogenic growth factor in the human placental development","volume":"76","author":"Dong","year":"2007","journal-title":"Biol Reprod"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102157_bib60","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/head.14305","article-title":"The use of erenumab for migraine prophylaxis during pregnancy: a case report and narrative review","volume":"62","author":"Vig","year":"2022","journal-title":"Headache"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102157_bib61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0333102420983292","article-title":"Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database","volume":"41","author":"Noseda","year":"2021","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib62","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102157_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102525","article-title":"In utero exposure to Azathioprine in autoimmune disease. Where do we stand?","volume":"19","author":"Belizna","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102157_bib64","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/rheumatology\/keac372","article-title":"Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine","volume":"62","author":"Reynolds","year":"2022","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102157_bib65","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/bdra.20583","article-title":"Early pregnancy azathioprine use and pregnancy outcomes","volume":"85","author":"Cleary","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/apt.12334","article-title":"Dutch Initiative on Crohn and Colitis. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease","volume":"38","author":"de Meij","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102157_bib67","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/gutjnl-2019-319129","article-title":"Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life","volume":"70","author":"Kanis","year":"2021","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/0961203313501402","article-title":"The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes","volume":"23","author":"Nalli","year":"2014","journal-title":"Lupus"},{"issue":"24","key":"10.1016\/j.eclinm.2023.102157_bib70","doi-asserted-by":"crossref","first-page":"e2989","DOI":"10.1212\/WNL.0000000000012084","article-title":"Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis","volume":"96","author":"Yeh","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44750","article-title":"Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy","volume":"5","author":"Hellwig","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib72","first-page":"1715","article-title":"Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry","volume":"267","author":"Hellwig","year":"2020","journal-title":"J\u00a0Neurol"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102157_bib73","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40263-013-0113-7","article-title":"Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review","volume":"27","author":"Fragoso","year":"2013","journal-title":"CNS Drugs"},{"issue":"20","key":"10.1016\/j.eclinm.2023.102157_bib74","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","article-title":"Pregnancy and fetal outcomes after interferon-\u03b2 exposure in multiple sclerosis","volume":"75","author":"Amato","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib75","first-page":"1250","article-title":"Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?","volume":"255","author":"Patti","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102157_bib76","first-page":"969","article-title":"Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series","volume":"24","author":"Fragoso","year":"2010","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102157_bib77","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1352458520929628","article-title":"Pregnancy outcome following first-trimester exposure to fingolimod: a collaborative ENTIS study","volume":"27","author":"Pauliat","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.eclinm.2023.102157_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103529","article-title":"Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population","volume":"59","author":"Andersen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"29","key":"10.1016\/j.eclinm.2023.102157_bib80","doi-asserted-by":"crossref","first-page":"E1129","DOI":"10.1503\/cmaj.202391","article-title":"The use and impact of monoclonal antibody biologics during pregnancy","volume":"193","author":"Pham-Huy","year":"2021","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13911","article-title":"Expected impact of immunomodulatory agents during pregnancy: a newborn's perspective","volume":"34","author":"Luo","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib82","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","article-title":"Evolution of maternofetal transport of immunoglobulins during human pregnancy","volume":"36","author":"Malek","year":"1996","journal-title":"Am J Reprod Immunol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib83","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1212\/NXI.0000000000000769","article-title":"Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases","volume":"7","author":"LaHue","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.eclinm.2023.102157_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329657","article-title":"Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis","author":"Landi","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib85","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib86","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1097\/MPH.0000000000001871","article-title":"Dysfunctional immune system reconstitution after rituximab exposure in utero","volume":"43","author":"Clark","year":"2021","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib87","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1212\/NXI.0000000000000734","article-title":"Rituximab, MS, and pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102157_bib89","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1177\/1352458517728813","article-title":"Natalizumab during pregnancy and lactation","volume":"24","author":"Proschmann","year":"2018","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib90","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","article-title":"Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study","volume":"21","author":"Ebrahimi","year":"2015","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib91","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib92","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/apt.15956","article-title":"In utero exposure to thiopurines\/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark","volume":"52","author":"N\u00f8rg\u00e5rd","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102157_bib93","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J\u00a0Crohns Colitis"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102157_bib94","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/ibd\/izz250","article-title":"Early discontinuation of infliximab in pregnant women with inflammatory bowel disease","volume":"26","author":"Truta","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib95","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41424-018-0018-3","article-title":"Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants","volume":"9","author":"Kattah","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib96","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0890334414566237","article-title":"Transfer of natalizumab into breast milk in a mother with multiple sclerosis","volume":"31","author":"Baker","year":"2015","journal-title":"J\u00a0Hum Lact"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102157_bib97","article-title":"Optimal timing of antenatal corticosteroid administration and preterm neonatal and early childhood outcomes","volume":"2","author":"Battarbee","year":"2020","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib98","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1210\/er.2013-1012","article-title":"Early-life glucocorticoid exposure: the hypothalamic-pituitary-adrenal axis, placental function, and long-term disease risk","volume":"34","author":"Braun","year":"2013","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102157_bib99","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/1471-0528.17027","article-title":"Antenatal corticosteroids to reduce neonatal morbidity and mortality: green-top Guideline No. 74","volume":"129","author":"Stock","year":"2022","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-2006-958162","article-title":"Pharmacokinetics of corticosteroids during pregnancy","volume":"24","author":"Pacheco","year":"2007","journal-title":"Am J Perinatol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102157_bib101","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2022.0483","article-title":"Evaluation of long-term outcomes associated with preterm exposure to antenatal corticosteroids: a systematic review and meta-analysis","volume":"176","author":"Ninan","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102157_bib102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1017\/S0033291718004129","article-title":"Associations of antenatal glucocorticoid exposure with mental health in children","volume":"50","author":"Wolford","year":"2020","journal-title":"Psychol Med"},{"issue":"19","key":"10.1016\/j.eclinm.2023.102157_bib103","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2020.3937","article-title":"Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children","volume":"323","author":"R\u00e4ikk\u00f6nen","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102157_bib104","first-page":"1102","article-title":"Multiple courses of antenatal corticosteroids for preterm birth study: outcomes in children at 5 years of age (MACS-5)","volume":"167","author":"Asztalos","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102157_bib105","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/archdischild-2021-321668","article-title":"School-aged neurodevelopmental outcomes for children born extremely preterm","volume":"106","author":"Doyle","year":"2021","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.eclinm.2023.102157_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1094698","article-title":"Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies","volume":"14","author":"Bromley","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102157_bib107","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/jnnp-2017-317368","article-title":"Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations","volume":"89","author":"Kinney","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eclinm.2023.102157_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211054956","article-title":"The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results","volume":"14","author":"Thiel","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102157_bib110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40264-022-01154-7","article-title":"A\u00a0landscape analysis of post-marketing studies registered in the EU PAS register and Clinicaltrials.gov focusing on pregnancy outcomes or breastfeeding effects: a contribution from the ConcePTION project","volume":"45","author":"Roque Pereira","year":"2022","journal-title":"Drug Saf"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:30Z","timestamp":1762899690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023003346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":104,"alternative-id":["S2589537023003346"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102157","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure to medication for neurological disease in pregnancy \u2013 time to consider the long-term implications?","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102157"}}